Burcon's Revenue Soars 273% as Commercialization Gains Traction

Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting a significant shift from technology validation to commercial execution. Burcon's first-quarter fiscal 2027 results show revenue surging 54% quarter-over-quarter and 273% year-over-year to $1.28 million, with active buying customers increasing from 30+ to 40. Repeat purchasing is on the rise, indicating growing demand for its plant-based protein products. Despite a $1.76 million inventory write-down that masked a narrower underlying gross loss, the company's commercial traction is improving. The key focus now is whether this momentum can support the substantial second-half revenue ramp needed to meet the prior CY26 sales target of $10 million, which would require approximately $7.9 million in sales during the second half. Burcon is also expanding its Galesburg production capacity and moving toward positive cash flow, with a planned financing of up to $8.1 million to bridge liquidity. The full announcement, including images and more details, can be accessed by clicking [here](https://stonegateinc.reportablenews.com/pr/stonegate-updates-coverage-on-burcon-nutrascience-corporation-tsx-bu-1q27). Stonegate Capital Partners, a capital markets advisory firm providing investor relations, equity research, and institutional outreach, issued the update. The company's progress in commercializing its technology is a positive sign for the plant-based protein industry.

The update underscores the importance of capacity and funding as execution levers. Burcon's revenue growth and expanding customer base are encouraging, but the company faces the challenge of ramping up production to meet sales targets. The planned financing and Galesburg expansion are critical to supporting this growth. Investors will be watching closely to see if Burcon can achieve its sales objectives and reach positive cash flow, which would validate its business model and technology.